NCT06669013View on ClinicalTrials.gov

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Bone SarcomaEmbryonal RhabdomyosarcomaAlveolar Rhabdomyosarcoma
Interventions
DRUG

dinutuximab beta

Chemotherapy + Immunotherapy (dinutuximab beta)

Trial Locations (1)

194362

RECRUITING

Kulyova Svetlana, Saint Petersburg

All Listed Sponsors
lead

N.N. Petrov National Medical Research Center of Oncology

OTHER

NCT06669013 - Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas | Biotech Hunter | Biotech Hunter